tiprankstipranks
Advertisement
Advertisement
Abbisko Wins FDA Orphan Drug Status for Achondroplasia Candidate ABSK061
PremiumCompany AnnouncementsAbbisko Wins FDA Orphan Drug Status for Achondroplasia Candidate ABSK061
1M ago
Abbisko Starts Phase II Trial of Irpagratinib Combo for Advanced Liver Cancer
Premium
Company Announcements
Abbisko Starts Phase II Trial of Irpagratinib Combo for Advanced Liver Cancer
1M ago
Abbisko Wins FDA Rare Pediatric Disease Status for Achondroplasia Drug ABSK061
Premium
Company Announcements
Abbisko Wins FDA Rare Pediatric Disease Status for Achondroplasia Drug ABSK061
2M ago
Abbisko Cayman Sets March Board Meeting to Approve 2025 Results and Consider Dividend
PremiumCompany AnnouncementsAbbisko Cayman Sets March Board Meeting to Approve 2025 Results and Consider Dividend
3M ago
Abbisko Advances FGFR4 Inhibitor Irpagratinib With First U.S. Patient Dosed in Global HCC Trial
Premium
Company Announcements
Abbisko Advances FGFR4 Inhibitor Irpagratinib With First U.S. Patient Dosed in Global HCC Trial
3M ago
Abbisko Wins FDA Fast Track for Precision Liver Cancer Drug Irpagratinib
Premium
Company Announcements
Abbisko Wins FDA Fast Track for Precision Liver Cancer Drug Irpagratinib
3M ago
Abbisko Therapeutics Reports Positive Phase II Results for NSCLC Treatment
PremiumCompany AnnouncementsAbbisko Therapeutics Reports Positive Phase II Results for NSCLC Treatment
5M ago
Abbisko Therapeutics Secures FDA Clearance for Pioneering Cancer Drug
Premium
Company Announcements
Abbisko Therapeutics Secures FDA Clearance for Pioneering Cancer Drug
5M ago
Abbisko Therapeutics Showcases Promising Phase III Results for TGCT Treatment
Premium
Company Announcements
Abbisko Therapeutics Showcases Promising Phase III Results for TGCT Treatment
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100